Education
About Us
Working with TipRanks
Follow Us
Apellis Pharmaceuticals Inc (APLS)
NASDAQ:APLS
RESEARCH TOOLSreports
Earnings Data
Report Date
May 01, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.34Last Year’s EPS
-0.54Same Quarter Last Year
Moderate Buy
Based on 16 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 28, 2025
|% Change Since: -3.27%
|Next Earnings Date:May 01, 2025
Earnings Call Sentiment|Positive
The earnings call highlights significant achievements in revenue growth, successful product launches, and pipeline advancements. However, there are challenges with temporary revenue impacts due to external factors and competitive pressures. Despite a net loss reported for the quarter, the company's strong financial position and strategic initiatives provide a positive outlook.Company Guidance
During the call, Apellis Pharmaceuticals, Inc. provided guidance for 2025, focusing on three strategic pillars: transforming the treatment of geographic atrophy (GA), maximizing the impact of EMPAVELLI in rare diseases, and advancing their innovative pipeline. The company reported significant milestones in 2024, including over 120% year-over-year US net revenue growth for Cipher and nearly $900 million in sales from XIFAV. Apellis plans to initiate a Phase 2 trial for a next-generation treatment for GA in the second quarter of 2025. They aim to secure leadership in the GA market, which is still in early growth stages, with an estimated less than 10% of patients receiving treatment. Additionally, the launch of EMPAVELLI in C3G and ICMPGN is anticipated in the second half of 2025, with plans to initiate Phase 3 trials for two new nephrology indications. Financially, Apellis reported total revenue of $781 million for 2024 and a net loss of $36.4 million for the fourth quarter, with $411 million in cash and cash equivalents at year-end. The company expects operating expenses in 2025 to remain stable compared to 2024.Record Year-Over-Year Revenue Growth
Cipher generated over 120% year-over-year US net revenue growth, contributing to total annual revenue of $781 million, nearly doubling from the previous year.
Successful Launch of XIFAVI
XIFAVI achieved nearly $900 million in sales in less than two years with 510,000 injections administered through December, maintaining over 60% market share.
Expansion and Regulatory Approvals
Received approval from the Therapeutic Goods Administration in Australia for XIFAVI and ongoing regulatory review in Switzerland.
Robust Pipeline Advancements
Presented positive Phase 3 VALION data for EMPHEREZ in C3G and ICF TGF, and initiated plans for a Phase 2 trial with a new combination treatment for GA.
Strong Financial Position
Ended the year with $411 million in cash and cash equivalents, with expectations to fund core business to profitability with existing cash and future product sales.
---
APLS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
APLS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 28, 2025 | $26.00 | $25.15 | -3.27% |
| Nov 05, 2024 | $28.56 | $28.08 | -1.68% |
| Aug 01, 2024 | $39.60 | $36.00 | -9.09% |
| May 07, 2024 | $48.81 | $43.90 | -10.06% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Apellis Pharmaceuticals Inc (APLS) report earnings?
Apellis Pharmaceuticals Inc (APLS) is schdueled to report earning on May 01, 2025, TBA Not Confirmed.
What is Apellis Pharmaceuticals Inc (APLS) earnings time?
Apellis Pharmaceuticals Inc (APLS) earnings time is at May 01, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is APLS EPS forecast?
APLS EPS forecast for the fiscal quarter 2025 (Q1) is -0.34.
---